Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Vaccines for preventing influenza in healthy children

Identifieur interne : 000112 ( 1968/Analysis ); précédent : 000111; suivant : 000113

Vaccines for preventing influenza in healthy children

Auteurs : S. Smith [Royaume-Uni] ; V. Demicheli ; C. Di Pietrantonj ; Ar Harnden ; T. Jefferson ; Nj Matheson ; A. Rivetti

Source :

RBID : ISTEX:A3C884CD87F6F1B0910D69181B3099E9FFA304CD

English descriptors

Abstract

Background: In children and adults the consequences of influenza are mainly absences from school and work, however the risk of complications is greatest in children and people over 65 years old. Objectives: To appraise all comparative studies evaluating the effects of influenza vaccines in healthy children; assess vaccine efficacy (prevention of confirmed influenza) and effectiveness (prevention of influenza‐like illness) and document adverse events associated with receiving influenza vaccines. Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005); OLD MEDLINE (1966 to 1969); MEDLINE (1969 to December 2004); EMBASE (1974 to December 2004); Biological Abstracts (1969 to December 2004); and Science Citation Index (1974 to December 2004). We wrote to vaccine manufacturers and a number of corresponding authors of studies in the review. Selection criteria: Any randomised controlled trials (RCTs), cohort and case‐control studies of any influenza vaccine in healthy children under 16 years old. Data collection and analysis: Two authors independently assessed trial quality and extracted data. Main results: Fifty‐one studies involving 263,987 children were included. Seventeen papers were translated from Russian. Fourteen RCTs and 11 cohort studies were included in the analysis of vaccine efficacy and effectiveness. From RCTs, live vaccines showed an efficacy of 79% (95% confidence interval (CI) 48% to 92%) and an effectiveness of 33% (95% CI 28% to 38%) in children older than two years compared with placebo or no intervention. Inactivated vaccines had a lower efficacy of 59% (95% CI 41% to 71%) than live vaccines but similar effectiveness: 36% (95% CI 24% to 46%). In children under two, the efficacy of inactivated vaccine was similar to placebo. Thirty‐four reports containing safety outcomes were included, 22 including live vaccines, 8 inactivated vaccines and 4 both types. The most commonly presented short‐term outcomes were temperature and local reactions. The variability in design of studies and presentation of data was such that meta‐analysis of safety outcome data was not feasible. Authors' conclusions: Influenza vaccines are efficacious in children older than two years but little evidence is available for children under two. There was a marked difference between vaccine efficacy and effectiveness. That no safety comparisons could be carried out emphasizes the need for standardisation of methods and presentation of vaccine safety data in future studies. It was surprising to find only one study of inactivated vaccine in children under two years, given recent recommendations to vaccinate healthy children from six months old in the USA and Canada. If immunisation in children is to be recommended as public‐health policy, large‐scale studies assessing important outcomes and directly comparing vaccine types are urgently required. Plain language summary: This review found nasal spray vaccines are better than injected vaccines at preventing influenza in children; neither were particularly good at preventing influenza‐like illness This review assessed how good influenza vaccines were in preventing 'flu' in children who are normally healthy. Nasal spray vaccines made from weakened influenza viruses, were better at preventing illness caused by the influenza virus than injected vaccines made from killed virus. Neither type was particularly good at preventing 'flu‐like illness' caused by other types of viruses. A large amount of information was collected comparing reactions in children who had received vaccines with those who had not. However, the vaccine types could not be compared because of the different ways the data were collected and presented in the studies. It was not possible to analyse the safety of vaccines from the studies due to the lack of standardisation in the information given. Very little information was found on the safety on inactivated vaccines, the most commonly used, in young children. Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Url:
DOI: 10.1002/ebch.24


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:A3C884CD87F6F1B0910D69181B3099E9FFA304CD

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Vaccines for preventing influenza in healthy children</title>
<author>
<name sortKey="Smith, S" sort="Smith, S" uniqKey="Smith S" first="S" last="Smith">S. Smith</name>
</author>
<author>
<name sortKey="Demicheli, V" sort="Demicheli, V" uniqKey="Demicheli V" first="V" last="Demicheli">V. Demicheli</name>
</author>
<author>
<name sortKey="Di Pietrantonj, C" sort="Di Pietrantonj, C" uniqKey="Di Pietrantonj C" first="C" last="Di Pietrantonj">C. Di Pietrantonj</name>
</author>
<author>
<name sortKey="Harnden, Ar" sort="Harnden, Ar" uniqKey="Harnden A" first="Ar" last="Harnden">Ar Harnden</name>
</author>
<author>
<name sortKey="Jefferson, T" sort="Jefferson, T" uniqKey="Jefferson T" first="T" last="Jefferson">T. Jefferson</name>
</author>
<author>
<name sortKey="Matheson, Nj" sort="Matheson, Nj" uniqKey="Matheson N" first="Nj" last="Matheson">Nj Matheson</name>
</author>
<author>
<name sortKey="Rivetti, A" sort="Rivetti, A" uniqKey="Rivetti A" first="A" last="Rivetti">A. Rivetti</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A3C884CD87F6F1B0910D69181B3099E9FFA304CD</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/ebch.24</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-DS452PKH-R/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000695</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000695</idno>
<idno type="wicri:Area/Istex/Curation">000695</idno>
<idno type="wicri:Area/Istex/Checkpoint">000459</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000459</idno>
<idno type="wicri:doubleKey">1557-6272:2006:Smith S:vaccines:for:preventing</idno>
<idno type="wicri:Area/Main/Merge">001554</idno>
<idno type="wicri:Area/Main/Curation">001529</idno>
<idno type="wicri:Area/Main/Exploration">001529</idno>
<idno type="wicri:Area/1968/Extraction">000112</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Vaccines for preventing influenza in healthy children</title>
<author>
<name sortKey="Smith, S" sort="Smith, S" uniqKey="Smith S" first="S" last="Smith">S. Smith</name>
<affiliation wicri:level="1">
<country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country>
<wicri:regionArea>Institute of Health Sciences, Oxford University, Old Road Headington, Oxford, OX3 7LF</wicri:regionArea>
<wicri:noRegion>OX3 7LF</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country>
<wicri:regionArea>Correspondence address: Institute of Health Sciences, Oxford University, Old Road Headington, Oxford, OX3 7LF</wicri:regionArea>
<wicri:noRegion>OX3 7LF</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Demicheli, V" sort="Demicheli, V" uniqKey="Demicheli V" first="V" last="Demicheli">V. Demicheli</name>
</author>
<author>
<name sortKey="Di Pietrantonj, C" sort="Di Pietrantonj, C" uniqKey="Di Pietrantonj C" first="C" last="Di Pietrantonj">C. Di Pietrantonj</name>
</author>
<author>
<name sortKey="Harnden, Ar" sort="Harnden, Ar" uniqKey="Harnden A" first="Ar" last="Harnden">Ar Harnden</name>
</author>
<author>
<name sortKey="Jefferson, T" sort="Jefferson, T" uniqKey="Jefferson T" first="T" last="Jefferson">T. Jefferson</name>
</author>
<author>
<name sortKey="Matheson, Nj" sort="Matheson, Nj" uniqKey="Matheson N" first="Nj" last="Matheson">Nj Matheson</name>
</author>
<author>
<name sortKey="Rivetti, A" sort="Rivetti, A" uniqKey="Rivetti A" first="A" last="Rivetti">A. Rivetti</name>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Evidence‐Based Child Health: A Cochrane Review Journal</title>
<title level="j" type="alt">EVIDENCE-BASED CHILD HEALTH: A COCHRANE REVIEW JOURNAL</title>
<idno type="ISSN">1557-6272</idno>
<idno type="eISSN">1557-6272</idno>
<imprint>
<biblScope unit="vol">1</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="367">367</biblScope>
<biblScope unit="page" to="522">522</biblScope>
<biblScope unit="page-count">156</biblScope>
<publisher>John Wiley & Sons, Ltd.</publisher>
<pubPlace>Chichester, UK</pubPlace>
<date type="published" when="2006-06">2006-06</date>
</imprint>
<idno type="ISSN">1557-6272</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1557-6272</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Alexandrova</term>
<term>Allantoic</term>
<term>Allergy</term>
<term>Analysis review</term>
<term>Antigenic</term>
<term>Applicable test</term>
<term>April</term>
<term>Attenuated</term>
<term>Attenuated vaccines</term>
<term>Belshe</term>
<term>Beutner</term>
<term>Bivalent</term>
<term>Burtseva</term>
<term>Child health</term>
<term>Chumakov</term>
<term>Cochrane</term>
<term>Cochrane collaboration</term>
<term>Cohort</term>
<term>Cohort studies</term>
<term>Cohort study</term>
<term>Colombo</term>
<term>Copyright</term>
<term>December</term>
<term>Desheva</term>
<term>Dos</term>
<term>Elshina</term>
<term>Estimable</term>
<term>Favours control vaccines</term>
<term>February</term>
<term>Grigoreva</term>
<term>Gruber</term>
<term>Gutman</term>
<term>Healthy children</term>
<term>Healthy children comparison</term>
<term>Hemagglutinin</term>
<term>Heterogeneity</term>
<term>Hoberman</term>
<term>Hospitalisation</term>
<term>Immunisation</term>
<term>Immunogenicity</term>
<term>Infectious diseases</term>
<term>Injector</term>
<term>Inoculated</term>
<term>Inoculation</term>
<term>Intramuscular</term>
<term>Intranasally</term>
<term>Irritability</term>
<term>January</term>
<term>John wiley sons</term>
<term>Levine</term>
<term>Local reactions</term>
<term>Maeda</term>
<term>Monovalent</term>
<term>Months cough</term>
<term>Months irritability</term>
<term>Morbidity</term>
<term>Nasal congestion</term>
<term>Notes allocation concealment</term>
<term>November</term>
<term>Other outcomes</term>
<term>Otitis</term>
<term>Otitis media</term>
<term>Overall effect</term>
<term>Overall effect favours treatment</term>
<term>Participant</term>
<term>Pediatrics</term>
<term>Pharyngitis</term>
<term>Piedra</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Principi</term>
<term>Randomised</term>
<term>Rcts</term>
<term>Reactogenicity</term>
<term>Recombinant</term>
<term>Relative risk</term>
<term>Rhinorrhea</term>
<term>Rudenko</term>
<term>Safety data</term>
<term>Safety outcomes</term>
<term>School children</term>
<term>Seroconversion</term>
<term>Seronegative</term>
<term>Slepushkin</term>
<term>Slobodniuk</term>
<term>Sore throat</term>
<term>Steinhoff</term>
<term>Subtotal</term>
<term>Subunit</term>
<term>Tonsillitis</term>
<term>Total events</term>
<term>Trivalent</term>
<term>Trivalent vaccine</term>
<term>Unvaccinated</term>
<term>Vaccinated</term>
<term>Vaccinated children</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccine safety</term>
<term>Vasilyeva</term>
<term>Viral</term>
<term>Whole vaccine</term>
<term>Young children</term>
<term>Zangwill</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Background: In children and adults the consequences of influenza are mainly absences from school and work, however the risk of complications is greatest in children and people over 65 years old. Objectives: To appraise all comparative studies evaluating the effects of influenza vaccines in healthy children; assess vaccine efficacy (prevention of confirmed influenza) and effectiveness (prevention of influenza‐like illness) and document adverse events associated with receiving influenza vaccines. Search strategy: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005); OLD MEDLINE (1966 to 1969); MEDLINE (1969 to December 2004); EMBASE (1974 to December 2004); Biological Abstracts (1969 to December 2004); and Science Citation Index (1974 to December 2004). We wrote to vaccine manufacturers and a number of corresponding authors of studies in the review. Selection criteria: Any randomised controlled trials (RCTs), cohort and case‐control studies of any influenza vaccine in healthy children under 16 years old. Data collection and analysis: Two authors independently assessed trial quality and extracted data. Main results: Fifty‐one studies involving 263,987 children were included. Seventeen papers were translated from Russian. Fourteen RCTs and 11 cohort studies were included in the analysis of vaccine efficacy and effectiveness. From RCTs, live vaccines showed an efficacy of 79% (95% confidence interval (CI) 48% to 92%) and an effectiveness of 33% (95% CI 28% to 38%) in children older than two years compared with placebo or no intervention. Inactivated vaccines had a lower efficacy of 59% (95% CI 41% to 71%) than live vaccines but similar effectiveness: 36% (95% CI 24% to 46%). In children under two, the efficacy of inactivated vaccine was similar to placebo. Thirty‐four reports containing safety outcomes were included, 22 including live vaccines, 8 inactivated vaccines and 4 both types. The most commonly presented short‐term outcomes were temperature and local reactions. The variability in design of studies and presentation of data was such that meta‐analysis of safety outcome data was not feasible. Authors' conclusions: Influenza vaccines are efficacious in children older than two years but little evidence is available for children under two. There was a marked difference between vaccine efficacy and effectiveness. That no safety comparisons could be carried out emphasizes the need for standardisation of methods and presentation of vaccine safety data in future studies. It was surprising to find only one study of inactivated vaccine in children under two years, given recent recommendations to vaccinate healthy children from six months old in the USA and Canada. If immunisation in children is to be recommended as public‐health policy, large‐scale studies assessing important outcomes and directly comparing vaccine types are urgently required. Plain language summary: This review found nasal spray vaccines are better than injected vaccines at preventing influenza in children; neither were particularly good at preventing influenza‐like illness This review assessed how good influenza vaccines were in preventing 'flu' in children who are normally healthy. Nasal spray vaccines made from weakened influenza viruses, were better at preventing illness caused by the influenza virus than injected vaccines made from killed virus. Neither type was particularly good at preventing 'flu‐like illness' caused by other types of viruses. A large amount of information was collected comparing reactions in children who had received vaccines with those who had not. However, the vaccine types could not be compared because of the different ways the data were collected and presented in the studies. It was not possible to analyse the safety of vaccines from the studies due to the lack of standardisation in the information given. Very little information was found on the safety on inactivated vaccines, the most commonly used, in young children. Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Demicheli, V" sort="Demicheli, V" uniqKey="Demicheli V" first="V" last="Demicheli">V. Demicheli</name>
<name sortKey="Di Pietrantonj, C" sort="Di Pietrantonj, C" uniqKey="Di Pietrantonj C" first="C" last="Di Pietrantonj">C. Di Pietrantonj</name>
<name sortKey="Harnden, Ar" sort="Harnden, Ar" uniqKey="Harnden A" first="Ar" last="Harnden">Ar Harnden</name>
<name sortKey="Jefferson, T" sort="Jefferson, T" uniqKey="Jefferson T" first="T" last="Jefferson">T. Jefferson</name>
<name sortKey="Matheson, Nj" sort="Matheson, Nj" uniqKey="Matheson N" first="Nj" last="Matheson">Nj Matheson</name>
<name sortKey="Rivetti, A" sort="Rivetti, A" uniqKey="Rivetti A" first="A" last="Rivetti">A. Rivetti</name>
</noCountry>
<country name="Royaume-Uni">
<noRegion>
<name sortKey="Smith, S" sort="Smith, S" uniqKey="Smith S" first="S" last="Smith">S. Smith</name>
</noRegion>
<name sortKey="Smith, S" sort="Smith, S" uniqKey="Smith S" first="S" last="Smith">S. Smith</name>
<name sortKey="Smith, S" sort="Smith, S" uniqKey="Smith S" first="S" last="Smith">S. Smith</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/1968/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000112 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/1968/Analysis/biblio.hfd -nk 000112 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    1968
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:A3C884CD87F6F1B0910D69181B3099E9FFA304CD
   |texte=   Vaccines for preventing influenza in healthy children
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021